Provided By Globe Newswire
Last update: Apr 6, 2022
SAN DIEGO, April 06, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced the acceptance of two abstracts presenting preclinical data on its systemic therapeutics delivery system for presentation at the Controlled Release Society (CRS) 2022 Annual Meeting. CRS is an international gathering of experts in the design, development, and implementation of novel drug delivery technologies. This year’s meeting is focused on advanced delivery science and will take place in Montreal, Canada, July 11-15, 2022.